<DOC>
	<DOCNO>NCT00783432</DOCNO>
	<brief_summary>The purpose study determine Astepro Nasal Spray ( 0.1 % azelastine hydrochloride ) safe Astelin Nasal Spray ( 0.1 % azelastine hydrochloride )</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability Nasal Spray Patients With Chronic Allergic Nonallergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>1 . Male female patient 12 year age old establish history ( &gt; 1 year ) rhinitis due perennial allergy , nonallergic trigger vasomotor rhinitis ( VMR ) . 2 . Provide write informed consent/pediatric assent . If patient minor , parent legal guardian must give write informed consent 3 . Willing able comply study requirement , include daily use medication one year period , even symptoms bothersome . 4 . General good health free disease concomitant treatment could interfere interpretation study result determine investigator sponsor 's medical officer 5 . Patients receive immunotherapy ( antigen desensitization ) must stable maintenance regimen least 30 day first study visit ( adjustment regimen follow brief period miss injection preclude participation ) 1 . The use investigational drug within 30 day prior screen . No investigational product permit use conduct study 2 . Presence hypersensitivity drug similar azelastine either sorbitol sucralose ( SplendaÂ® brand sweetener ) 3 . Women pregnant nursing 4 . Women childbearing potential abstinent practice medically acceptable method contraception . Female patient must practice acceptable contraceptive technique 30 day randomization agree continue use treatment 30 day last dose study drug . Oral , intrauterine , implantable , injectable contraceptive , double barrier form contraception acceptable medication include dose , device method must stable least 30 day first dose study drug . 5 . Nasal disease ( ) likely affect deposition intranasal medication , sinusitis , rhinitis medicamentosa clinically significant nasal polyposis nasal structural abnormality 6 . Patients asthma ( exception mild , intermittent asthma ) significant pulmonary disease Chronic Obstructive Pulmonary Disease 7 . Patients known history alcohol drug abuse 8 . Existence surgical medical condition , opinion investigator sponsor , might significantly alter evaluation study 9 . Clinically relevant abnormal history and/or physical finding , opinion investigator sponsor , would interfere objective study may preclude compliance study procedures 10 . Study site staff , immediate relative study site staff , individual would access clinical study protocol</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>